Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 47 Breast Neoplasms 34 Breast Neoplasms, Male 3 Neoplasms 2 Neoplasm Metastasis 2 Infertility 2 Advanced Breast Cancer 2 Sexual Dysfunction, Physiological 1 Recurrence 1 Prostate Adenocarcinoma 1 Primary Ovarian Insufficiency 1 Osteoporosis 1 Osteitis Deformans 1 Leiomyoma 1 Hot Flashes 1 Hemorrhage 1 Breast Cancer Invasive 1 Anemia 1 Advanced Prostate Cancer 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 28 Rituximab 16 pomalidomide 13 Gemcitabine 12 Lenalidomide 11 Cisplatin 11 Bortezomib 11 Paclitaxel 10 Cyclophosphamide 8 Carboplatin 8 carfilzomib 7 selinexor 5 daratumumab 5 Drug Therapy 5 Doxorubicin 5 Cytarabine 5 ibrutinib 4 Vincristine 4 Temozolomide 4 Prednisone 4 Docetaxel 4 Calcium Dobesilate 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Cetuximab 3 Bendamustine Hydrochloride 3 venetoclax 2 ofatumumab 2 galiximab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × Goserelin × Clear all

NCT00439751 2016-07-12

ELAAT

Ontario Clinical Oncology Group (OCOG)

Phase 3 Completed

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡